Nanomaterial-Mediated Nucleic Acid Delivery for Pancreatic Cancer Therapeutics

Urmica Nandy1, Abul Kalam Azad Mandal1, Pranav2

  • 1School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore Campus, Vellore 632014, India.

PubMed

Insights

Nanomaterials offer a promising delivery system for nucleic acid therapeutics (NATs) to combat aggressive pancreatic cancer (PC). This review explores nanomaterial-based NAT delivery systems, highlighting their potential for precision medicine in PC treatment.

Area of Science:

  • Oncology
  • Nanotechnology
  • Biomedical Engineering

Background:

  • Pancreatic cancer (PC) is a lethal malignancy with limited treatment options, necessitating novel therapeutic strategies.
  • Traditional therapies face challenges in targetability, recurrence, and side effects, driving the need for precision medicine approaches.
  • Nucleic acid therapeutics (NATs) show promise for PC by targeting genetic pathways, but efficient delivery remains a hurdle.

Purpose of the Study:

  • To systematically review the development and application of nanomaterial-based delivery systems for NATs in pancreatic cancer therapy.
  • To evaluate the benefits, drawbacks, and translational potential of various nanocarriers for NAT delivery against PC.
  • To compare the efficacy of nanomaterial-mediated NAT delivery in different preclinical models, including 2D and 3D cell cultures and in vivo studies.

Main Methods:

  • Comprehensive literature review of nanomaterial-based nucleic acid therapeutics for pancreatic cancer.
  • Analysis of preclinical data comparing NAT delivery in wild-type and drug-resistant PC cells.
  • Evaluation of NAT delivery in 2D and 3D cell culture models, alongside in vivo and clinical studies.

Main Results:

  • Nanomaterials demonstrate high biocompatibility and tunable properties, making them effective carriers for NATs.
  • Nanocarriers enhance tumor-specific accumulation and protect NATs from degradation, improving targetability.
  • Preclinical assessments show promise for nanomaterial-mediated NAT delivery in various PC models, with 3D cultures offering improved relevance to in vivo systems.

Conclusions:

  • Nanomaterial-based NAT delivery systems represent a significant advancement in precision medicine for pancreatic cancer.
  • Further research into 3D cell culture models can bridge the gap between preclinical findings and clinical translation.
  • Optimized nanocarrier design and delivery strategies are crucial for overcoming current limitations and advancing NATs for PC treatment.